NCT03794349 2026-02-18
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
Children's Oncology Group
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT04743661 2026-02-05
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
Pediatric Brain Tumor Consortium
Phase 2 Active not recruiting
NCT02975882 2025-01-14
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed
NCT00311584 2014-09-30
Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
Children's Oncology Group
Phase 2 Completed
NCT00099125 2014-01-24
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00004078 2013-06-14
Irinotecan in Treating Children With Refractory Solid Tumors
Children's Oncology Group
Phase 2 Completed